The expert panel members recognize that BsAbs with targets other than BCMA, such as GPRC5D and Fc receptor-homolog 5 (FcRH5), may have variable infection rates and risks, depending on doses, dose intervals, and patient characteristics, and future recommendations may need to take into account these variables. This evidence concerns the gene GPRC5D and infection.